Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
40.97
-0.23 (-0.56%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
November 29, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
November 23, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
November 19, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs
November 18, 2021
From
Bristol Myers Squibb
Via
Business Wire
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
November 15, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Launches Could It Be HCM? Campaign to Increase Awareness of Hypertrophic Cardiomyopathy (HCM), the Most Common Inherited Heart Disease
November 15, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Take Part in Wolfe Research Virtual Healthcare Conference
November 10, 2021
From
Bristol Myers Squibb
Via
Business Wire
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
November 08, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
November 08, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for a Broad Range of Hematologic Diseases
November 04, 2021
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases
November 03, 2021
From
Bristol Myers Squibb
Via
Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
October 28, 2021
From
The Schall Law Firm
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
October 27, 2021
From
The Schall Law Firm
Via
Business Wire
Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
October 27, 2021
From
Bristol Myers Squibb
Via
Business Wire
BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
October 26, 2021
From
Lieff Cabraser Heimann & Bernstein, LLP
Via
Business Wire
Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)
October 25, 2021
From
Bristol Myers Squibb
Via
Business Wire
The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to Be Trained
October 22, 2021
SOURCE: Bristol Myers Squibb Company
Via
3BL Media
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma …
October 21, 2021
From
Bristol Myers Squibb
Via
Business Wire
The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained
October 20, 2021
From
Bristol Myers Squibb
Via
Business Wire
Celebrating the Science That Transforms Patients' Lives
October 18, 2021
SOURCE: Bristol Myers Squibb Company
Via
3BL Media
Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
October 15, 2021
From
Bristol Myers Squibb
Via
Business Wire
Team BMS Moves for Minutes to Benefit Special Olympics
October 14, 2021
SOURCE: Bristol Myers Squibb Company
Via
3BL Media
Exposures
COVID-19
Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
October 13, 2021
From
Bristol Myers Squibb
Via
Business Wire
OLA and PRIDE Alliance PBRGs teamed up to host an empowering storytelling forum
October 11, 2021
SOURCE: Bristol Myers Squibb Company
Via
3BL Media
BRISTOL MYERS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
October 07, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
October 07, 2021
From
Bristol Myers Squibb
Via
Business Wire
Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Bristol-Myers Squibb Company
October 06, 2021
From
Entwistle & Cappucci
Via
Business Wire
Bristol Myers Squibb to Hold Investor Event on November 16
October 01, 2021
From
Bristol Myers Squibb
Via
Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
October 01, 2021
From
Bristol Myers Squibb
Via
Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
October 01, 2021
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.